Research Progress on Sclerostin Antibody

doi:10.13701/j.cnki.kqyxyj.2019.12.004

Abstract

Abstract: Sclerostin is a negative regulator of bone formation and inhibits bone formation by inhibiting the Wnt/β-catenin signaling pathway. Sclerostin antibody (Scl-Ab) ensures the transmission of the Wnt/β-catenin signaling pathway by antagonizing the negative regulation of sclerostin on bone formation. Compared to other osteogenic drugs, Scl-Ab can stimulate osteogenic activity without stimulating osteoclast activity. A variety of Scl-Ab have been developed. Romosozumab, the most representative antibody, has completed clinical phase III trials, demonstrating that it can significantly promote bone formation and inhibit bone resorption. However, clinical efficacy and safety of Scl-Ab is still unclear and requires further investigation and discussion. Therefore, this review was conducted in order to provide theoretical basis for experimental research and clinical treatment.

Key words: sclerostin antibody, Romosozumab, bone regeneration

LIANG Tingting, GUO Lvhua. Research Progress on Sclerostin Antibody[J]. Journal of Oral Science Research, 2019, 35(12): 1119-1121.

References

[1] Opar A. Late-stage osteoporosis drugs illustrate challenges in the field [J]. Nat Rev Drug Discov, 2009, 8(10): 757-758.
[2] Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis [J]. J Bone Miner Res, 2009, 24(4): 578-588.
[3] Yakar N, Guncu GN, Akman AC, et al. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG [J]. Cytokine, 2019, 113: 433-439.
[4] Jacobsen CM. Application of anti-Sclerostin therapy in non-osteoporosis disease models [J]. Bone, 2017, 96:18-23.
[5] Liu YS, Liu XB, Qiu YY, et al. Molecular mechanism of Wnt signal pathway in multiple myeloma cell line H929 cell autophagy [J]. Eur Rev Med Pharmacol Sci, 2018, 22(11):3327-3332.
[6] Choi J, Lee K, Kang M, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors [J]. Bioorg Med Chem Lett, 2018, 28(6): 1116-1121.
[7] Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis [J]. N Engl J Med, 2016, 375(16): 1532-1543.
[8] Qin W, Li X, Peng Y, et al. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats [J]. J Bone Miner Res, 2016, 31(7):1482.
[9] Spatz JM, Ellman R, Cloutier AM, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading [J]. J Bone Miner Res, 2013, 28(4):865-874.
[10] Hay E, Bouaziz W, Funck-Brentano T, et al. Sclerostin and bone aging: a mini-review [J]. Gerontology, 2016, 62(6): 618-623.
[11] Herrero S, Pico Y. Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment [J]. Eur J Pharmacol, 2016, 779: 8-21.
[12] Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody [J]. J Bone Miner Res, 2011, 26(1): 19-26.
[13] McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density [J]. N Engl J Med, 2014, 370(5): 412-420.
[14] Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis [J]. Int J Womens Health, 2015, 7: 565-580.
[15] McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women [J]. J Bone Miner Res, 2014, 29(4): 935-943.
[16] Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density [J]. J Bone Miner Res, 2015, 30(2): 216-224.
[17] Recknor CP, Recker RR, Benson CT, et al. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density [J]. J Bone Miner Res, 2015, 30(9): 1717-1725.
[18] Wang FS, Wu RW, Lain WS, et al. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration [J]. Bone, 2018, 112: 24-34.
[19] Yao Q, Ni J, Hou Y, et al. Expression of sclerostin scFv and the effect of sclerostin scFv on healing of osteoporotic femur fracture in rats [J]. Cell Biochem Biophys, 2014, 69(2): 229-235.
[20] 倪杰, 侯宇, 艾笛, 等. 骨硬化素单链抗体对去卵巢模型大鼠骨质疏松性骨折愈合的影响[J]. 中国药房, 2013, 24(45): 4240-4242.
[21] Florio M, Gunasekaran K, Stolina M, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair [J]. Nat Commun, 2016, 7:11505.
[22] Napimoga MH, Nametala C, Da SF, et al. Involvement of the Wnt-beta-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis [J]. J Clin Periodontol, 2014, 41(6):550-557.
[23] Kuchler U, Schwarze UY, Dobsak T, et al. Dental and periodontal phenotype in sclerostin knockout mice [J]. Int J Oral Sci, 2014, 6(2):70-76.
[24] Lehnen SD, Gotz W, Baxmann M, et al. Immunohistochemical evidence for sclerostin during cementogenesis in mice [J]. Ann Anat, 2012,194(5): 415-421.
[25] Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis [J]. J Bone Miner Res, 2013, 28(11): 2347-2356.
[26] Han P, Ivanovski S, Crawford R, et al. Activation of the canonical Wnt signaling pathway induces cementum regeneration [J]. J Bone Miner Res, 2015, 30(7):1160-1174.